These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 12678836)
81. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356 [TBL] [Abstract][Full Text] [Related]
82. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol. Harikumar KG; Coudrat T; Desai AJ; Dong M; Dengler DG; Furness SGB; Christopoulos A; Wootten D; Sergienko EA; Sexton PM; Miller LJ Front Endocrinol (Lausanne); 2021; 12():789957. PubMed ID: 34950108 [TBL] [Abstract][Full Text] [Related]
83. Evidence for a functional role of cholecystokinin receptors in the rat thyroid gland. Ginda WJ Folia Histochem Cytobiol; 2001; 39(4):331-4. PubMed ID: 11766768 [TBL] [Abstract][Full Text] [Related]
84. The effect of centrally administered CCK-receptor antagonists on food intake in rats. Corp ES; Curcio M; Gibbs J; Smith GP Physiol Behav; 1997 Jun; 61(6):823-7. PubMed ID: 9177553 [TBL] [Abstract][Full Text] [Related]
85. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Szewczyk JR; Laudeman C Curr Top Med Chem; 2003; 3(8):837-54. PubMed ID: 12678836 [TBL] [Abstract][Full Text] [Related]
86. Role of cholecystokinin and opioid peptides in control of food intake. Baile CA; McLaughlin CL; Della-Fera MA Physiol Rev; 1986 Jan; 66(1):172-234. PubMed ID: 2868468 [TBL] [Abstract][Full Text] [Related]
87. Role of cholecystokinin in the control of food intake. Peikin SR Gastroenterol Clin North Am; 1989 Dec; 18(4):757-75. PubMed ID: 2693351 [TBL] [Abstract][Full Text] [Related]
88. Major biological actions of CCK--a critical evaluation of research findings. Fink H; Rex A; Voits M; Voigt JP Exp Brain Res; 1998 Nov; 123(1-2):77-83. PubMed ID: 9835394 [TBL] [Abstract][Full Text] [Related]
90. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). de Tullio P; Delarge J; Pirotte B Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792 [TBL] [Abstract][Full Text] [Related]
91. Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target. Miller LJ; Desai AJ Trends Endocrinol Metab; 2016 Sep; 27(9):609-619. PubMed ID: 27156041 [TBL] [Abstract][Full Text] [Related]
92. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Moran TH; Bi S Philos Trans R Soc Lond B Biol Sci; 2006 Jul; 361(1471):1211-8. PubMed ID: 16815799 [TBL] [Abstract][Full Text] [Related]
94. Strategies for design of non peptide CCK1R agonist/antagonist ligands. García-López MT; González-Muñiz R; Martín-Martínez M; Herranz R Curr Top Med Chem; 2007; 7(12):1180-94. PubMed ID: 17584140 [TBL] [Abstract][Full Text] [Related]
95. CCK1 antagonists: are they ready for clinical use? Peter SA; D'Amato M; Beglinger C Dig Dis; 2006; 24(1-2):70-82. PubMed ID: 16699265 [TBL] [Abstract][Full Text] [Related]
96. Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. Pathak V; Flatt PR; Irwin N Peptides; 2018 Feb; 100():229-235. PubMed ID: 29412823 [TBL] [Abstract][Full Text] [Related]
97. Cholecystokinin: role in thermoregulation and other aspects of energetics. Szelényi Z Clin Chim Acta; 2010 Mar; 411(5-6):329-35. PubMed ID: 20036221 [TBL] [Abstract][Full Text] [Related]
98. The ontogeny of postingestive inhibitory stimuli: examining the role of CCK. Weller A Dev Psychobiol; 2006 Jul; 48(5):368-79. PubMed ID: 16770766 [TBL] [Abstract][Full Text] [Related]